Evaluating the Immunogenicity and Safety of a Smallpox Vaccine to Monkeypox in Healthy Japanese Adults: A Single-Arm Study
Authors:
- Noriko TomitaNTNoriko Tomita
- Eriko MorinoEMEriko Morino
- Junko Terada-HirashimaJTJunko Terada-Hirashima
- Yukari UemuraYUYukari Uemura
- Yosuke ShimizuYSYosuke Shimizu
- Sho SaitoSSSho Saito
- Tetsuya SuzukiTSTetsuya Suzuki
- Nobumasa OkumuraNONobumasa Okumura
- Haruka IwasakiHIHaruka Iwasaki
- Hideki EbiharaHEHideki Ebihara
- Masayuki ShimojimaMSMasayuki Shimojima
- Wataru SugiuraWSWataru Sugiura
Open Access
Abstract
Monkeypox (mpox) is an acute exanthematous disease caused by the monkeypox virus (MPXV). Since May 2022, patients with mpox have been reported worldwide, mainly in Europe and the Americas. In Japan, LC16”KMB,” which is a smallpox vaccine derived from a dried cell culture, against mpox, has been approved. Although inoculation with a smallpox vaccine has been recommended to prevent MPXV infection, the immunogenicity of the smallpox vaccine against the MPXV is unclear, and information regarding postvaccination safety is scarce. We present the protocol for a single-arm open-label study to investigate the immunogenicity and safety of LC16”KMB” against the MPXV in healthy Japanese adults. The primary endpoint is the seroconversion rate of neutralizing antibodies against the MPXV on postvaccination day 28. The secondary endpoints are the seroconversion rates against the MPXV on postvaccination days 14 and 168; the seroconversion rates against the vaccinia virus on postvaccination days 14, 28, and 168; the incidence of mpox until day 168; and adverse and serious adverse events until postvaccination days 28 and 168. These results will pave the way for larger comparative studies using other smallpox vaccines to evaluate the test vaccine’s safety and efficacy in preventing mpox.Keywords
Funding Information
- Ministry of Health, Labour, and Welfare (JPMH20HA2005)
This publication has 20 references indexed in Scilit:
- Freeze-dried live attenuated smallpox vaccine prepared in cell culture “LC16-KAKETSUKEN”: Post-marketing surveillance study on safety and efficacy compliant with Good Clinical PracticeVaccine, 2015
- Human MonkeypoxClinical Infectious Diseases, 2013
- Safety and Immunogenicity of LC16m8, an Attenuated Smallpox Vaccine in Vaccinia-Naive AdultsThe Journal of Infectious Diseases, 2011
- Clinical and Immunological Response to Attenuated Tissue-Cultured Smallpox Vaccine LC16m8JAMA, 2009
- Human Monkeypox: An Emerging Zoonotic DiseaseFuture Microbiology, 2007
- Evaluation of Human-to-Human Transmission of Monkeypox from Infected Patients to Health Care WorkersClinical Infectious Diseases, 2005
- Smallpox as a Biological WeaponJAMA, 1999
- Re-emergence of monkeypox in Africa: a review of the past six yearsBritish Medical Bulletin, 1998
- The Transmission Potential of Monkeypox Virus in Human PopulationsInternational Journal of Epidemiology, 1988
- Human Monkeypox: Clinical Features of 282 PatientsThe Journal of Infectious Diseases, 1987